Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0CBDJ | ISIN: KYG8167W1380 | Ticker: SMZ1
Tradegate
18.11.26 | 17:20
0,619 Euro
+1,28 % +0,008
Branche
Biotechnologie
Aktienmarkt
Hong Kong 50
1-Jahres-Chart
SINO BIOPHARMACEUTICAL LTD Chart 1 Jahr
5-Tage-Chart
SINO BIOPHARMACEUTICAL LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,6180,63318.11.
0,6080,63318.11.

Aktuelle News zur SINO BIOPHARM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiCMBI Raises SBP GROUP TP to HKD9 as Multiple Innovative Drugs Included in National Medical Insurance4
SINO BIOPHARM Aktie jetzt für 0€ handeln
09.11.SBP GROUP Announces Phase II Clinical Data for TQ-A33346
09.11.SBP GROUP (01177): VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL DATA OF TQ-A3334 "TLR7 AGONIST" PRESENTED AT THE 2026 AASLD2
06.11.UOB Kay Hian Raises SBP GROUP TP to HKD7.5, USD7 Billion Partnership Expected to Drive Growth Next Year3
05.11.Sino Biopharm Surges After Striking Over USD7 Billion Cancer Drug Deal With Boehringer Ingelheim18
04.11.Boehringer forges $7bn alliance with China's SBP Group19
04.11.Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs11
04.11.Boehringer signs oncology deal with Sino Biopharm worth up to $7.4bn6
04.11.SBP GROUP Reaches Collaboration With Boehringer Ingelheim, Potential Proceeds USD7 Billion6
04.11.Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies581Partnership provides opportunities to further expand Boehringer Ingelheim's portfolio of antibody-drug conjugates (ADCs) and T-cell engagers (TcEs)Agreement reinforces Boehringer Ingelheim's long-term...
► Artikel lesen
04.11.SBP GROUP (01177): VOLUNTARY ANNOUNCEMENT - ENTER INTO PARTNERSHIP WITH BOEHRINGER INGELHEIM WITH POTENTIAL TOTAL DEAL VALUE OF US$7 BILLION2
27.10.SBP GROUP Two Hepatitis B New Drugs Included in Breakthrough Therapy Designation Program8
27.10.SBP GROUP (01177): VOLUNTARY ANNOUNCEMENT - TQ-A3334 "TLR7 AGONIST" AND TQA3605 "CORE PROTEIN ALLOSTERIC MODULATOR" GRANTED BREAKTHROUGH THERAPY DESIGNATION ...3
26.10.SBP GROUP Releases Clinical Data for Self-Developed Innovative Drug TQB21023
26.10.SBP GROUP (01177): VOLUNTARY ANNOUNCEMENT - DATA FROM TWO CLINICAL STUDIES OF TQB2102 "HER2 BIPARATOPIC ADC" PRESENTED AT 2026 ESMO5
22.10.SBP GROUP Repurchases 10M Shares on Thu for Nearly HKD50M2
22.10.SBP GROUP (01177): NEXT DAY DISCLOSURE RETURN9
21.10.SBP GROUP TQC2731 Phase III Clinical Trial for Chronic Rhinosinusitis With Nasal Polyps Completes Patient Enrollment3
21.10.SBP GROUP (01177): VOLUNTARY ANNOUNCEMENT - COMPLETION OF ALL PARTICIPANTS ENROLLMENT IN THE PHASE III REGISTRATIONAL CLINICAL TRIAL OF TQC2731 INJECTION ...2
19.10.Transcenta Appoints Former Sino Biopharmaceutical CFO Jennie Ma5
1 2 3 4 5 Weiter >>
87 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1